GSK's China Licensing Deals, Electra Therapeutics' $300M IPO and Scholar Rock’s Drug Approval Highlight Biopharma Trends
GlaxoSmithKline (GSK) has been active in licensing deals with Chinese drug developers since the start of 2025. The company secured five such agreements, including two this month for next-generation cancer therapies involving antibody technology. These partnerships reflect a broader industry trend where pharmaceutical firms are increasingly acquiring innovative drugs developed in China. In parallel, biotech IPOs have seen a resurgence in 2026 with over 20 companies raising capital so far this year. Electra Therapeutics recently joined the $300 million club after pricing its offering, marking an industry milestone that matches the record set during the pandemic peak of 2021. Meanwhile, Scholar Rock received U.S. regulatory approval for Isembyld, a novel treatment for spinal muscular atrophy. Despite positive analyst projections and broad prescribing guidelines, the stock has experienced significant volatility following concerns about potential safety risks linked to fractures.
Tickers: $GSK